Fineline Cube

Follow:
14486 Articles
Biocytogen Licenses RenMice Antibody to Tubulis, Boosting ADC Development
CompanyDeals

Biocytogen Licenses RenMice Antibody to Tubulis, Boosting ADC Development

Rona Therapeutics RN3161 siRNA Targets INHBE, Submits Australian Trial Application
Drug

Rona Therapeutics RN3161 siRNA Targets INHBE, Submits Australian Trial Application

Bio-Thera Partners with Jamjoom Pharma to Launch BAT2306 Biosimilar in MENA
CompanyDeals

Bio-Thera Partners with Jamjoom Pharma to Launch BAT2306 Biosimilar in MENA

ZSCO Invests 790 m RMB in Guobang Pharma, Launches Strategic Partnership
CompanyDeals

ZSCO Invests 790 m RMB in Guobang Pharma, Launches Strategic Partnership

CSPC Pharmaceutical Group Secures NMPA Approval for SYH2066 in RSV Trials
CompanyDrug

CSPC Pharmaceutical Group Secures NMPA Approval for SYH2066 in RSV Trials

Genrix Succeeds with Telikibart Phase 3, Targets Atopic Dermatitis
CompanyDrug

Genrix Succeeds with Telikibart Phase 3, Targets Atopic Dermatitis

HitGen and BioAge Launch Phase I Study of BGE‑102, a Novel NLRP3 Inhibitor
CompanyDeals

HitGen and BioAge Launch Phase I Study of BGE‑102, a Novel NLRP3 Inhibitor

Lion TCR Secures FDA Approval for LioCyx‑M004, Launching Phase Ib/II Trial in Chronic Hepatitis B
Drug

Lion TCR Secures FDA Approval for LioCyx‑M004, Launching Phase Ib/II Trial in Chronic Hepatitis B

Biokin Pharma Secures Breakthrough Therapy Designation for izalontamab with BMS
CompanyDrug

Biokin Pharma Secures Breakthrough Therapy Designation for izalontamab with BMS

Siemens Healthineers Diagnostics Sale: Blackstone, CVC, KKR Explore €6 B Deal
CompanyDeals

Siemens Healthineers Diagnostics Sale: Blackstone, CVC, KKR Explore €6 B Deal

Baheal’s 24% Take‑over of Tianjin Jikun Secures Rights to Pulmonary Fibrosis Drug JK1033
CompanyDeals

Baheal’s 24% Take‑over of Tianjin Jikun Secures Rights to Pulmonary Fibrosis Drug JK1033

BMS Sells 60% Shanghai Stake to Hillhouse Capital, Shifting Focus to Growth
CompanyDeals

BMS Sells 60% Shanghai Stake to Hillhouse Capital, Shifting Focus to Growth